ABSTRACT. Objective. Serum 14-3-3η is a novel joint-derived proinflammatory mediator implicated in the pathogenesis of rheumatoid arthritis (RA). In our study, we assessed the diagnostic utility of 14-3-3η and its association with standard clinical and serological measures. Methods. A quantitative ELISA was used to assess 14-3-3η levels. Early (n = 99) and established patients with RA (n = 135) were compared to all controls (n = 385), including healthy subjects (n = 189). The sensitivity, specificity, positive and negative predictive values of 14-3-3η, and the likelihood ratios (LR) for RA were determined through receiver-operator curve analysis. The incremental value of adding 14-3-3η to anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) in diagnosing early and established RA was assessed.
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects about 1.5% of the population. It is driven by multiple pathophysiological factors and manifests with high heterogeneity both among and within patients along the disease course. If left untreated, RA results in severe joint destruction leading to impaired physical function and workplace disability 1, 2, 3, 4 .
Supporting the concept of a "window of opportunity" for therapeutic intervention, several studies have reported on the benefits of initiating disease-modifying antirheumatic drug (DMARD) therapy within the first 12 weeks following symptom onset. It is now widely accepted that identification of RA in its earliest stages, assessment of disease severity at diagnosis, and implementation of an effective treatment strategy can significantly improve a patient's prognosis 5 . In recognition of this, new RA classification criteria were established in 2010 that focus on defining the disease by its earlier features 6 . Classification of RA according to these new criteria relies on the evaluation of joint involvement, measurement of acute-phase reactants and serological markers, and assessment of symptom duration. For serological measurements, higher weighting is ascribed to patients who have higher titers of both anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF) compared to those with low levels or who are seronegative. Seronegativity in both early and established RA remains a major limitation of these 2 markers highlighting the need for new complementary markers that will improve diagnostic sensitivity 7, 8 . New markers are also needed to better stratify patients into different risk categories because current markers only account for 32% of the total variance in predicting joint destruction 9 .
In RA, certain markers may be present as a consequence of the disease as "bystanders" and others may be more intimately linked to the disease pathogenesis. In 2007, Kilani, et al demonstrated by Western blot analysis that a novel soluble biomarker, 14-3-3η , was present at significantly higher levels in the synovial fluid and serum of patients with arthritis compared to healthy individuals and that serum levels correlated strongly with the matrix metalloproteinases (MMP) MMP-1 and MMP-3 10 .
There are 7 isoforms of the 14-3-3 family of intracellular chaperone proteins (α/β, γ, δ/ζ, ε, η, θ/τ, σ). These highly conserved proteins are acidic at physiologic pH, possess a molecular weight of about 28 kDa, and share more than 50% amino acid homology between isoforms. Structurally, they have 9 α helices with variable amino-and carboxyl-termini. Through their N-terminus, the 14-3-3 proteins either homo-or hetero-dimerize, forming a cup-like structure known as the amphipathic groove. Through this groove, 14-3-3 proteins interact with more than 200 intracellular proteins, thereby regulating an array of biological processes including protein synthesis, cellular metabolism, protein trafficking, signal transduction, and cytoskeletal transport 10 .
Of the isoforms, only 14-3-3η was present in synovial fluid with levels of at least 5-fold higher than those found in matched sera, implicating the joint as the likely source of 14-3-3η. Externalization of 14-3-3η is believed to be mediated in part through exosomes because this family of proteins has been described as a key component of these microvesicles 11, 12 . In the extracellular environment, at concentrations present in the serum of patients with RA, soluble 14-3-3η possesses ligand activity, preferentially activating cells of the innate immune system 10 . Soluble 14-3-3η acts through signaling cascades such as the extracellular signal-regulated kinase and p38 pathway to upregulate proinflammatory cytokines, including interleukin 1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α), and factors that are involved in joint degradation such as MMP-9 and receptor activator of nuclear factor-κB ligand (RANKL) 13 .
In our study, we assessed the discriminative power of serum 14-3-3η for established RA using healthy subjects and disease controls to determine the sensitivity and specificity of 14-3-3η using a 14-3-3η quantitative ELISA. We also assessed to what degree it enhanced diagnostic utility when combined with standard clinical and serological variables in early RA.
MATERIALS AND METHODS
Patients with RA and controls. Demographics for all participants, as well as clinical characteristics of the early and established cohorts with RA, are provided in Table 1 . Serum 14-3-3η levels were measured in banked samples (stored at -80°C) from 135 established patients with RA classified according to the American College of Rheumatology (ACR) 1987 criteria 14 . Patients with established RA were from the Rheumatoid Arthritis Pharmacovigilance Program of Outcomes Research Team cohort from the University of Alberta, Canada (n = 75), and from Bioreclamation Inc. (n = 60). These patients were taking standard DMARD, but naive to biological therapy. For comparison to the established group with RA, serum 14-3-3η levels were analyzed from a total of 385 controls: 189 presumed healthy subjects (from Quest Diagnostics and BioChemed LLC), 72 patients with arthritis without RA (patients with ankylosing spondylitis from the University of Alberta, classified according to the modified New York Criteria, n = 67; gout, n = 5), 25 patients with connective tissue disorders (patients with systemic lupus erythematosus, n = 10; systemic sclerosis, n = 5; Sjögren syndrome, n = 5; and osteoporosis, n = 5), 45 patients with various inflammatory diseases (patients with Crohn disease, n = 10; ulcerative colitis, n = 10; psoriasis, n = 10; type 1 diabetes, n = 10; and multiple sclerosis, n = 5), 24 with psoriatic arthritis (PsA; from the Academic Medical Center, Netherlands, 12 of whom had visible signs of joint damage as determined through radiographic adjudication), and 30 patients with osteoarthritis (OA; Mount Sinai Hospital, Canada). Diagnoses of disease controls were confirmed by the attending physician.
To examine 14-3-3η expression in early RA, serum levels were measured in 99 patients who were naive of DMARD therapy and had a median disease duration of 3.4 months. Patients with early RA were from the Toronto Early Arthritis Cohort (TEACH; Mount Sinai Hospital, Canada, n = 25), the Intensified-Combination Therapy with Rheumatoid Arthritis cohort (iCOBRA; Vrije Universiteit University Medical Center, the Netherlands, n = 12), and the Reade prospective cohort with early RA (Reade, the Netherlands, n = 62). The median [(with interquartile range (IQR)] and mean (SD), respectively, disease duration for the cohorts with early RA were TEACH -1.0 months (0.0-3.7) and 7.8 (42.4) months; COBRA -1.0 months (1.0-2.0) and 1.4 (1.1) months; and Reade 4.2 months (2.9-3.7) and 6.8 (6.7) months. Serum 14-3-3η levels of patients with early RA were compared to patients with OA (n = 30, from Mount Sinai Hospital, Canada) because the differential diagnosis between OA and early RA is often difficult for primary practitioners. Serum 14-3-3η levels were also compared to healthy individuals and all controls.
Our study was performed in accordance with the Helsinki Declaration. Written informed consent was obtained from all study participants and ethics approval was obtained from the Health Research Ethics Board of the University of Alberta, the Ethical Review Board of Vrije Universiteit University of Amsterdam Medical Center, the Jan van Breemen Institute, the Mount Sinai Health Ethics Review Board of the University of Toronto, and the Western Institutional Review Board for the Quest Diagnostics Nichols Institute. Serum 14-3-3η, RF, and ACPA measurements. Serum 14-3-3η levels were measured using the quantitative 14-3-3η ELISA (Augurex Life Sciences Corp.), with the exception of 134 healthy subjects whose levels were measured using the laboratory-developed test at the Quest Diagnostics Nichols Institute. The 2 assays use comparable clinical cutoffs for positivity (0.19 vs 0.20 ng/ml), and substantial equivalence testing demonstrated that the 14-3-3η values on the 2 different assays were within 15% of each other (r = 0.94, p < 0.0001).
The development, validation, and calibration of the commercially available quantitative 14-3-3η ELISA (Augurex assay) is extensively detailed in the appended supplement (supplementary data available online at jrheum.org), as is the concordance between the Augurex assay and the laboratory-developed test (Quest Diagnostics). Both assays use the same monoclonal antibodies in a 2-sided, sandwich ELISA, and the same calibrator was used to generate the standard curve. Briefly, in the Augurex assay, serum samples were diluted 1:20 using the supplied assay dilution buffer. One hundred µl of either the corresponding calibrator or sample were incubated in a 96-well plate shaker for 2 h at 50 rpm and 27°C. Following incubation, the plates were washed 4 consecutive times with wash buffer, and then incubated with the prediluted horseradish peroxidaseconjugate antibody for 1 h at room temperature without shaking. The plates were washed 4 additional times and subsequently incubated with 3,3', 5,5'-tetramethylbenzidine substrate for 30 min, at which time the reaction was terminated through the addition of 1N hydrochloric acid stop solution. Serum 14-3-3η levels were quantified using a 4-parameter logistic regression curve generated against the diluted calibrators. The accuracy of the results was evaluated by examining the precision of the back-calculated concentrations of each of the calibrators and the corresponding measurements of 3 quality control samples with 14-3-3η levels within the linear range of the assay. All clinical samples were run in duplicate. Samples with levels below the reportable range were assigned a concentration of 0 ng/ml, and those with levels above the upper limit were defined as having 14-3-3η levels > 20 ng/ml. RF and ACPA assays were performed as per manufacturers' protocols (RF: Quanta Lite RF IgG ELISA, RF Quanta Lite RF IgA ELISA, RF Quanta Lite RF IgM ELISA; ACPA: RF Quanta Lite CCP3 IgG ELISA). The assay calibrators were run in duplicates with patient samples singly.
Statistical methods. Descriptive statistics were used to express clinical and serological measurements according to disease category and healthy controls. Median 14-3-3η serum expression differences between the RA and control groups were tested for statistically significant differences using a 2-tailed Mann-Whitney U test. To compare more than 2 groups, the Kruskal-Wallis test with the posthoc Dunn's Multiple Comparison method was used to determine whether statistical significance existed across the groups. If a statistical difference was observed, the significance between the 2 groups was determined using the Mann-Whitney U test. Receiver-operating characteristic (ROC) curves were used to evaluate the diagnostic utility of 14-3-3η as estimated by the area under the curve (AUC), the corresponding likelihood ratios (LR) at various 14-3-3η serum concentration cutoffs, and the corresponding positive and negative predictive values (PPV; NPV). The additional diagnostic value added by the inclusion of 14-3-3η was assessed in early and established RA (in addition to RF or ACPA alone and together). An incremental benefit/change was calculated as follows:
[ arthropathies (ankylosing spondylitis = 67, gout = 5); CTD: connective tissue disorders (systemic lupus erythematosus n = 10, systemic sclerosis n = 5, Sjögren syndrome n = 5, and osteoporosis n = 5); ID: inflammatory diseases (Crohn disease n = 10, ulcerative colitis n = 10, psoriasis n = 10, type 1 diabetes n = 10, and multiple sclerosis n = 5); PsA: psoriatic arthritis; OA: osteoarthritis. Further, sensitivity and specificity of RF, ACPA, and RF and/or ACPA with and without inclusion of 14-3-3η was calculated for both the groups with early and established RA with reference to the healthy controls and all controls (healthy plus disease controls). Because 14-3-3η has been described as a mechanistic marker that participates in the perpetuation of inflammation and joint damage based on its in vitro cell stimulatory effects, we compared patients who are 14-3-3η-positive and -negative for disease activity and status using the Mann-Whitney U test. The relationship between 14-3-3η and other serological markers was assessed using the Spearman's rank correlation coefficient procedure for non-normally distributed data and Pearson's product-moment correlation for normally distributed variables. Distribution normality was established by the Shapiro-Wilk normality test.
All statistical analyses were completed with Prism 6 (GraphPad Software Inc.) or JMP10 (SAS Institute Inc.). An α of p < 0.05 denoted statistical significance.
RESULTS
Specificity of 14-3-3η for established RA. Median (IQR) serum 14-3-3η concentrations (ng/ml) were significantly higher (p < 0.0001) in patients with established RA [1.12 ng/ml (0.22-6.87)] as compared to healthy individuals [0.00 ng/ml (0.00-0.06)] and all controls [0.02 ng/ml (0.00-0.09); Figure 1A ]. ROC curve analysis comparing established RA with healthy subjects demonstrated a significant (p < 0.0001) AUC of 0.89 (95% CI, 0.85-0.93; Figure 1B ). At a cutoff of ≥ 0.19 ng/ml, the ROC curve yielded a sensitivity of 77.0%, a specificity of 92.6%, an LR positivity of 10.4, a PPV of 0.70, and an NPV of 0.80. When comparing established RA with all controls, the same cutoff yielded a sensitivity of 77.4% and specificity of 86.0%. At cutoffs of ≥ 0.40 ng/ml and ≥ 0.80 ng/ml, 2 serum 14-3-3η concentrations below the observed group median in our established RA study population, the specificity increased to 90.4% and 94.0%, and the corresponding sensitivities were 68.9% (LR = 7.2) and 55.6% (LR = 9.3).
Although levels in PsA were numerically higher than in other control groups ( Figure 1A ), the Kruskal-Wallis ANOVA across all of the control groups did not reveal any significant differences among any of the control groups tested. However, Dunn's posttest revealed that levels in erosive PsA were significantly different from those in patients with nonerosive PsA (p < 0.05), but not when compared to patients with psoriasis alone. The Mann-Whitney U test also revealed that median 14-3-3η levels were significantly higher in patients with erosive PsA (0.23 ng/ml) than in the nonerosive group (0.0 ng/ml, p = 0.026). Figure 1C illustrates that 14-3-3η levels were similar in patients with psoriasis and nonerosive PsA (Dunn's test = NS, p = 0.33). Serum 14-3-3η levels in PsA were significantly lower than in established (p < 0.0001) and early RA (p = 0.0005). Serum 14-3-3η expression in early RA. ANOVA (p = 0.27) revealed that there were no significant differences in 14-3-3η serum expression between the 3 early groups with RA (Reade, TEACH, and iCOBRA). Consequently, they were combined for further analyses. Median (IQR) serum 14-3-3η concentrations (ng/ml) were significantly higher (p < 0.0001) in patients with early RA [0.76 ng/ml (0.03-5.61)] when compared to patients with OA (Table  1A) . Median 14-3-3η levels in early RA were also significantly higher than in healthy individuals (p < 0.0001) and all controls (p < 0.0001). ROC curve analysis comparing early RA with healthy controls demonstrated a significant (p < 0.0001) AUC of 0.81 (95% CI, 0.76-0.87; Figure 1D ). At a cutoff of ≥ 0.19 ng/ml, the ROC curve yielded a sensitivity of 63.6%, a specificity of 92.6%, an LR positivity of 8.6, a PPV of 0.57, and an NPV of 0.78. When comparing early RA with OA at the level of ≥ 0.19 ng/ml, the sensitivity and specificity were 63.6% and 83.3%, respectively, with an LR of 3.8. At cutoffs of ≥ 0.40 ng/ml and ≥ 0.80 ng/ml, the specificity increased to 93.3% and 96.7%, and the corresponding sensitivities were 59.6% (LR = 8.8) and 49.5% (LR = 14.9). When comparing early RA with all controls at the ≥ 0.19 ng/ml, the sensitivity and specificity were 63.6% and 86.0%, respectively, with an LR of 4.5. At cutoffs of ≥ 0.40 ng/ml and ≥ 0.80 ng/ml, the specificity increased to 90.4% and 94.0%, and the corresponding sensitivities were 59.6% (LR = 6.2) and 48.5% (LR = 8.1). Tables 2A and 2B illustrate the relationship between the levels of 14-3-3η and clinical and serological variables in the cohorts with early and established RA, respectively. As expected, a significant correlation between ACPA and RF was observed in both cohorts. Similarly, serum 14-3-3η also correlated with the titers of ACPA and RF.
Relationship of serum 14-3-3η with clinical measures. The correlation matrices presented in
Because ACPA and RF are routinely used together to inform an RA diagnosis, the incremental benefit of adding 14-3-3η to each of the markers was assessed. As illustrated in Table 3A , of the 99 patients assessed with early RA, 58 (59%), 56 (57%), and 63 (64%) were positive for ACPA, RF, and 14-3-3η, respectively. As expected in a cohort with advanced RA, the proportion of patients with positivity in all 3 markers was greater in the cohort with established RA (ACPA 79%, RF 85%, and 14-3-3η 77%). When assessing the cohort with early RA, adding RF to ACPA increased diagnostic detection from 59% to 72%. Adding 14-3-3η to ACPA also resulted in an identification rate of 72%. However, when combined with RF, 14-3-3η increased the diagnostic detection from 57% to 75%. All 3 markers together identified 78% of this patient population with early RA. In the cohort with established RA, RF and/or 14-3-3η had a greater identification rate than ACPA and/or RF (94% vs 88%). When combining 14-3-3η with ACPA or when combining all 3 biomarkers together, the identification rate increased marginally to 96%.
The sensitivity and specificity of RF, ACPA, and RF and/or ACPA with or without the inclusion of 14-3-3η is presented in Table 3B . Regardless of the comparison, the addition of 14-3-3η led to notable increases in sensitivity with generally smaller losses in specificity. When comparing the addition of either 14-3-3η or RF to ACPA, there were similar increases in sensitivity, but the resulting specificity was superior with the 14-3-3η-ACPA pairing as compared to the RF-ACPA pairing (i.e., in the early RA vs healthy cohorts, the RF-ACPA sensitivity/specificity was 0.71/0.84, whereas the 14-3-3η-ACPA values were 0.71/0.92). Baseline 14-3-3η positivity and disease severity. The results presented in Table 4 demonstrate that 14-3-3η-positive patients with RA had more severe disease with significantly higher median baseline Disease Activity Score (6.3 vs 5.7, p = 0.026) and Health Assessment Questionnaire measures (1.9 vs 1.0, p = 0.001) compared to the 14-3-3η-negative patients with RA. Worse disease based on 14-3-3η positivity is further corroborated by the significantly higher levels in acute-phase reactants (erythrocyte sedimentation rate, C-reactive protein) and serological measures (RF, ACPA) in the patient group positive for 14-3-3η (Table 3 and Figure 2 ).
DISCUSSION
Our data showed that 14-3-3η discriminated between patients with early RA and other autoimmune disorders, patients with OA, and healthy controls. This discriminatory capacity was comparable to the established biomarkers RF and ACPA. Serum 14-3-3η assessment enhanced the detection of RA over either RF or ACPA alone by 32% and 22%, respectively, in patients with early RA. Because there is no correlation with established clinical variables of disease activity in RA, it is unlikely that 14-3-3η nonspecifically reflects inflammation. Rather, our data suggest that it may reflect a more severe phenotype of disease. Our data support the case for incorporating serological markers such as 14-3-3η into the framework of the 2010 ACR/European League Against Rheumatism classification criteria for use in diagnosing RA.
Correlation analysis demonstrated minimal associations of 14-3-3η with other clinical or laboratory variables, suggesting that 14-3-3η provides independent information toward the diagnosis of RA. Results should be regarded as of Rheumatology
The Journal on August 20, 2014 -Published by www.jrheum.org Downloaded from preliminary in view of the limited sample size in the cohort with early RA and the selection of patients for high disease activity in the cohort with established RA. Nevertheless, this biomarker is modifiable and there are data that serum levels as well as the short-term change in serum levels are associated with clinical response to anti-TNF-α agents 15 .
The role of ACPA in the diagnosis of RA is now well established, largely based on prospective data indicating that it has a PPV of about 95% for the development of RA in populations of patients with undifferentiated arthritis, though its NPV is only about 60-70% 16, 17 . Our data describe the first analysis of the 14-3-3η biomarker in cross-sectional cohorts, which is an essential first step in the investigation of a biomarker's diagnostic utility. Further analyses are now warranted in unselected cohorts with undifferentiated arthritis who have been followed prospectively to determine which patients develop RA. ACPA is also of clinical value because it has been shown to possess predictive capacity for radiographic progression in RA 1, 18 . However, studies in early RA have shown that the contribution of ACPA together with other predictive clinical variables contributes only about 32% of the total risk for radiographic progression 9 . Because cross-sec tional data suggest that 14-3-3η may be independently associated with radiographic damage in both RA and PsA 19 , and because it has been shown to upregulate expression of MMP and RANKL, a prospective study is also warranted to examine its capacity as an independent predictor of radiographic progression.
We previously reported that 14-3-3η concentrations are 5-fold higher in synovial fluid than in matched serum 10 . In vitro data show that the soluble extracellular form of 14-3-3η activates several proinflammatory signaling cascades relevant to RA 13 . A notable exception contrasting with TNF is that 14-3-3η does not appear to signal through the p38MAP kinase and nuclear factor-κB pathways. Serum 14-3-3η has also been described as a potent inducer of MMP in vitro, and levels of 14-3-3η correlate with MMP expression in serum and synovial fluid of patients with RA, suggesting that it may play a role in the joint damage cascade 10, 13 . We have also reported data suggesting an association between serum 14-3-3η levels and radiographic damage in patients with PsA, also described herein. However, 14-3-3η levels are lower in PsA compared to RA, and detectable only in those patients with erosive PsA. Serum 14-3-3η is a constituent of exosomes, and following extracellular release has been shown to participate in a positive feedback interactive loop with TNF in promoting inflammation 13 . Thus, TNF stimulates expression of 14-3-3η while 14-3-3η stimulates expression of TNF, and this may be relevant to the finding that 14-3-3η is elevated in both patients with RA and patients with PsA with more severe radiographic changes. The 14-3-3η ELISA assay has undergone substantial preclinical validation, exhibiting strong analytical performance as determined by high sensitivity, assay precision of 9%, lack of significant cross-reactivity with other isoforms, absence of affect by potential interfering substances such as RF and various therapeutics used in RA (including infliximab), and absence of sample drift over time. The assay has also been validated according to several criteria proposed by the Outcome Measures in Rheumatology Soluble Biomarker Working Group 20 : it performs similarly in paired serum and plasma samples, the marker demonstrates stability over 3 days at room temperature and 4°C, and it exhibits limited variability according to age and sex (as described in the supplementary data available online at jrheum.org).
We have shown that 14-3-3η is a biomarker that discriminates both early and established RA when compared to healthy and disease controls that include patients with other arthropathies. Further, the discriminative ability of 14-3-3η was comparable to RF and ACPA, and enhanced their diagnostic capacity. Our work therefore supports continuing 
DEVELOPMENT, VALIDATION AND CALIBRATION OF THE 14-3-3η ASSAY
The 14-3-3η ELISA assay has undergone substantial preclinical validation, exhibiting strong analytical performance as determined by high sensitivity, assay precision of 9%, no significant cross-reactivity with other isoforms, no impact of dilution on quantitation, no impact of potential interfering substances such as RF and various therapeutics used in RA (including infliximab), and no sample drift over time.
The assay has also been validated according to several of the criteria proposed by the
OMERACT Soluble Biomarker Working Group (1). It performed similarly in paired serum
and plasma samples, demonstrated stability over 72 hours at room temperature and 4 o C, and was independent of age and sex.
Lastly, the Augurex 14-3-3ƞ ELISA in-vitro diagnostic medical test and the laboratory-developed test available through Quest Diagnostics were highly correlated (r =0.94).
ASSAY DEVELOPMENT
Validation of 14-3-3η protein standard. Human 14-3-3η was expressed as an untagged recombinant protein in E. coli and purified employing affinity and size-exclusion chromatography. The identity of 14-3-3η was confirmed through cDNA sequencing, amino acid analysis and an in-gel digest coupled with mass spectrometry. The 14-3-3η standard included in the assay is provided as a lyophilized standard that is reconstituted in an assay dilution buffer to a working concentration of 1000 pg/ml.
The human 14-3-3η (NP_003396) is 246 amino acids in length with an apparent molecular weight of 28.2 kDa, an isoelectric point (pI) of 4.84 and an estimated charge of -12.9 at physiologic pH.
Amino acid analysis (Table 1) confirmed the identity of the protein as the 14-3-3η protein, with further corroboration both by cDNA and mass spectrometry analyses (data not shown).
Production of anti-14-3-3η monoclonal antibodies. Monoclonal antibodies were raised to either two distinct synthetic peptides, each of which resides within a conserved region of the 14-3-3η protein and to the full length untagged recombinant E. coli-expressed 14-3-3η protein. Antibodies were initially screened to establish specificity for 14-3-3η using the seven 14-3-3 family members through immunoblot analysis. Antibodies deemed to be 14-3-3η monospecific were then tested for their ability to selectively immunoprecipitate both the recombinant and endogenous forms of 14-3-3η. Cell lysates were prepared as previously described (2) .
A library of 100 antibody clones was developed and through lead selection activities, 18 of the 100 clones were prioritized for assay development. Of these 18
antibodies, five were prioritized to enter assay development. The binding curves shown in Figure 1 demonstrate that the two lead antibodies selected for the 14-3-3η ELISA (enzyme-linked immunosorbent assay) are fully saturated within minutes of exposure to the recombinant 14-3-3η antigen, with the capture antibody (3-7F8) being fully saturated within approximately two minutes.
Monoclonal antibody pairing studies. Prioritized antibodies were evaluated by using biotin labeled antigen (to test for solid phase performance), followed by assessment of detection antibody performance using unlabeled antigen and biotin labeled monoclonal antibodies. Tables 2 and 3 show the respective pairing data for the two lead clones used as either the 'capture' or 'conjugate' antibody. Based on the signal-to-noise ratios, the most favorable pairing was with 3-7F8 used as the capture antibody and 4-8F10 as the conjugate.
Assay method development. The performance of this sequential assay format was evaluated to determine the optimal sample incubation time, temperature and the impact of assay motion variations. To determine the optimal conjugate antibody and assay dilution buffers, the effects of various pH and salt concentrations were measured to identify the appropriate buffer composition that yielded the greatest signal-to-noise ratio.
The effects of different chelators, preservatives and detergents were examined.
Plate Coating Conditions. The optimal working concentration of the capture antibody (3-7F8) of 4 µg/ml was established through titration of the capture antibody from concentrations ranging from 0.1 to 10 µg/ml. Based on these findings, the coating antibody was diluted to a working concentration with use of a phosphate-containing buffer.
Plate Blocking Conditions. Following antibody coating, the plates were blocked overnight using a phosphate containing buffer with salt, detergent and protein. After blocking, the plates were dried and placed into a sealed pouch with a standard desiccant.
Conjugate Antibody Formulation. The 14-3-3η monoclonal antibody, 4-8F10, was used as the conjugate. Various chelators and preservatives were evaluated as part of the final buffer formulation. The conjugated form of the 4-8F10 antibody was diluted to a working concentration using a Tris Buffer with stabilizer, salt, detergent, protein and non-azide preservatives.
Assay Buffer Formulation. The assay buffer incorporated into the 14-3-3η assay was a Tris-based buffer containing salt, protein and non-azide preservatives.
Wash Buffer. The incorporated wash buffer was a 20X stock concentrate diluted with dH20 to a 1X working solution. The wash buffer was a phosphate-based buffer containing sodium chloride and non-azide preservatives.
Assay Time Determination. To identify the optimal sample incubation time, samples were incubated on a plate shaker at 500 rpm for incubation periods ranging from 30 to 240 minutes with shaking. Incubation for 120 minutes was found to be optimal (data not shown).
Assay Temperature. To determine the optimal assay performance temperature, samples were incubated on the plate at room temperature, 4 o C, 27 o C and 37 o C. The results showed no significant performance difference; however incubation at 27 o C was selected.
Serum Tolerance. Serum tolerance testing was performed over 8 dilutions (1:2 -1:100 serum dilution) to determine the optimal dilution which provided the most reliable 14-3-3η concentration. The dilution which provided the most reliable quantitation of 14-3-3η was 1:20.
ASSAY VALIDATION
Precision. Both the intra-and inter-assay precision were examined across the linear range of the assay with three serum samples consisting of low (130 pg/ml), medium (326 pg/ml) and high (740 pg/ml) serum 14-3-3η levels. Samples were run in duplicate using one reagent lot on a single microtiter plate reader. For intra-assay precision, the samples were tested in replicates of 20. For inter-assay precision, samples were run in duplicate 20 times over three days by three different operators.
Intra-assay and inter-assay precision results were beneath 10% (Table 4) , which is within the acceptable variance range as proposed in the draft validation criterion by the OMERACT soluble biomarker sub-committee (1).
Cross reactivity. To assess the impact of the 14-3-3 isoforms on the quantification of 14-3-3η, the six different 14-3-3 family members (α/β, ε, γ, σ, θ/τ, and δ/ζ) were added to a sample at 100 times the concentration (100,000 pg/ml) of the highest 14-3-3η standard (1000 pg/ml). The 14-3-3η assay displayed no significant cross-reactivity when 14-3-3η
was tested in the presence of the other 14-3-3 isoforms (Table 5 ).
Interference testing. The impact of endogenous and exogenous analytes commonly present in the serum of RA patients on the quantification of 14-3-3η was evaluated using a 14-3-3η positive serum sample from a patient with RA.
Using an acceptance criterion of values within 15%, the results indicated that the tested common serum analytes do not significantly impact the quantification of 14-3-3η (Table   6 ).
Linearity, recovery and non-interference of 14-3-3ƞ quantitation by rheumatoid factor.
The potential effects of rheumatoid factor (RF) interference on the 14-3-3ƞ ELISA invitro diagnosic test were evaluated in three separate experiments. For each of the three experiments, three to four serial dilutions were performed 1:1, ensuring that the first sample dilution read within the linear range of the14-3-3ƞ ELISA assay.
Experiment 1: Linearity of Dilution in Samples with High Rheumatoid Factor
Titres. Nine samples from patients with RA with high 14-3-3ƞ protein and high RF concentrations were evaluated across serial dilutions. Quantitation of 14-3-3ƞ protein was highly reproducible in the presence of high RF levels (Table 7) , with a mean 14-3-3ƞ concentration variability across serial dilutions of 7.2%. This data demonstrates that the quantification of 14-3-3η is not impacted by the presence of rheumatoid factor titres.
Experiment 2: Serum samples from 4 patients with RA with known 14-3-3ƞ and RF concentrations were evaluated. Each sample was mixed 1:1 with a negative control to examine 14-3-3ƞ percent recovery between the expected and measured 14-3-3ƞ
concentrations. Mixing of the high RF and 14-3-3ƞ positive samples with the negative control serum revealed that the mean recovery was 96% (percent recovery ranged from 88% to 105%; Table 8 ), which was well within the OMERACT acceptable range of 10%.
This data corroborates the findings from Experiment #1 which demonstrates that the presence of RF does not impact 14-3-3η's quantitation.
Experiment 3: Five 14-3-3ƞ negative RA patient serum samples with high RF levels were serially diluted to determine whether any of the negative samples became positive for 14-3-3ƞ. All of the high-RF, 14-3-3ƞ-negative samples remained 14-3-3ƞ
negative through all serial dilutions, indicating that the high RF levels present in these negative samples did not confound the 14-3-3ƞ assessment (Table 9) .
High-dose hook effect. The hook effect was evaluated by titering varying amounts of the 14-3-3η standard ranging from 7.81 -1,000,000 pg/ml.
The results presented in Figure 2 demonstrate that the standards used to generate the standard curve to quantify the serum levels of 14-3-3η. Concentrations of 14-3-3η found in patient serum are found within the linear range of the 14-3-3η assay making the quantification of 14-3-3η in patient samples reliable.
A high-dose hook effect was observed at 10,000 or 104 pg/ml of 14-3-3η which is 10 times greater than the highest standard used in the 14-3-3η assay.
Sample drift. Thirty-five dilutions of a single sample were prepared, each of which was pipetted in duplicate across a single plate in order to evaluate the impact of timeassociated sample drift.
There was minimal sample drift over time as more than two-thirds of the values were within 10% of the original 14-3-3η concentration ( Figure 3 ).
Biomarker stability. The short-term stability of 14-3-3η was examined in serum over 72
hours at room temperature and at 4 o C in seven samples with known 14-3-3η values.
The results demonstrated that 14-3-3η was highly stable with median CV% at room temperature and at 4 o C of 103% (R=91-106%) and 104% (R=95-108%), respectively.
Biomarker stability was also examined by assessing three samples over three freezethaw cycles and by sequentially assessing six samples for up to two years of storage at -80C. Serum 14-3-3η was stable over three freeze-thaw cycles with the median recovery being 109% (range of 92% to 129%; Table 10 ). Long-term storage studies determined that samples negative for 14-3-3η remained negative while those with levels above the upper limit of quantification of >20 ng/ml had effectively equivalent levels ( Figure 4) . Stability of 14-3-3η was further confirmed using samples within the linear range of the assay with the median CV% found to be 104% of the original values (range of 89% to 128%).
Effect of age and sex. One hundred healthy controls, consisting of 50 males (median age 54, range 19-78 years) and 50 females (median age 55, range 18-79 years), had their serum 14-3-3η concentration assessed to establish whether it was impacted by either sex or age. Pearson product-moment correlations were used to evaluate the relationship of age and 14-3-3η concentration and a two-tailed Mann-Whitney U test was conducted to assess whether there was a significant difference in 14-3-3η concentration between sexes.
No significant correlation between age and 14-3-3η concentration was found (r = concentration between these two assays.
Agreement was found in 37 out of the 40 samples evaluated (Table 11) CV: coefficient of variation Table 5 . 14-3-3η Cross-reactivity testing.
TABLES
Cross Reactant Percent Recovery 14-3-3α/β 0.01%
14-3-3ε <0.01%
14-3-3γ <0.01%
14-3-3σ 0.02%
14-3-3θ/τ <0.01%
14-3-3δ/ζ 0.02% RF: rheumatoid factor. Table 9 . Non-interference of 14-3-3ƞ quantitation by rheumatoid factor, experiment 3. 
